PNEUMONIA is the #7 most commonly reported adverse reaction for MEPOLIZUMAB, manufactured by GlaxoSmithKline LLC. There are 4,419 FDA adverse event reports linking MEPOLIZUMAB to PNEUMONIA. This represents approximately 2.5% of all 173,706 adverse event reports for this drug.
Patients taking MEPOLIZUMAB who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
PNEUMONIA4,419 of 173,706 reports
PNEUMONIA is a less commonly reported adverse event for MEPOLIZUMAB, but still significant enough to appear in the safety profile.
Other Side Effects of MEPOLIZUMAB
In addition to pneumonia, the following adverse reactions have been reported for MEPOLIZUMAB:
PNEUMONIA has been reported as an adverse event in 4,419 FDA reports for MEPOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is PNEUMONIA with MEPOLIZUMAB?
PNEUMONIA accounts for approximately 2.5% of all adverse event reports for MEPOLIZUMAB, making it a notable side effect.
What should I do if I experience PNEUMONIA while taking MEPOLIZUMAB?
If you experience pneumonia while taking MEPOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.